News & Events
Vedanta Biosciences to Present at Upcoming Investor Conferences (opens in a new tab)
CAMBRIDGE, MA, April 29, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences: Wells Fargo Virtual Private Biotech…
Genetic Analysis AS: Publication of Annual Report 2023 (opens in a new tab)
Oslo, Norway, April 18, 2024 – Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the Annual Report for the financial year of 2023. The Annual Report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). The company’s auditor has stated in his auditor’…
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT (opens in a new tab)
Clinical data readout expected end of Q3 2024 SER-155 and other Seres microbiome therapeutic candidates have potential to expand microbiome therapeutic franchise into additional medically vulnerable patient populations CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 9, 2024– Seres Therapeutics, Inc.…
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference (opens in a new tab)
CAMBRIDGE, MA, March 6, 2024 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL fr…
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (opens in a new tab)
VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts SER-155 Phase 1b…
Year-end report January – December 2023 (opens in a new tab)
Oslo, Norway, February 29, 2024 – Genetic Analysis AS (the “Company”, Ticker: GEAN) hereby publishes the year-end report for the period 1 January – December 31, 2023. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO…
Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 28, 2024– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on March 5, 2024 at 8:30 a.m. ET to discuss fourth quarter and full year 2023…
Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 27, 2024– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will participate in a panel discussion at the Cowen 44th Annual…
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 26, 2024– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of March 25th , following David Arkowitz’s…
Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit (opens in a new tab)
The post Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit appeared first on Genetic Analysis.…
Genetic Analysis AS: Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit (opens in a new tab)
Oslo, Norway, November 26, 2024 – Genetic Analysis AS (the “Company”, Ticker: GEAN) is proud to announce that its GA-map® Sample Collection Kit has obtained CE-IVD marking under the In Vitro Diagnostic Regulation (EU) 2017/746. The GA-map® Sample Collection Kit is a device that simplifies the sample collection process,…
Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises (opens in a new tab)
Genetic Analysis AS’ (“GA” or the “Company”) subsequent offering to existing shareholders, for which the subscription period ended on December 22, 2023 (the “Subsequent Offering”), has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). During the period December 11 – Decem…
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155 (opens in a new tab)
VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023 Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts SER-155 Phase 1b…
Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 4, 2024– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 , at…
Genetic Analysis announces final outcome of the subsequent offering to existing shareholders (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis announces preliminary outcome of the subsequent offering to existing shareholders (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis partners up to enter the consumer market with GA-map® (opens in a new tab)
OSLO, NORWAY – December 21, 2023: Today, Microbiome DX company Genetic Analysis AS (“GA” or the “Company”) announces a collaboration with Comono AS (“Comono”) to develop a digital business platform for microbiome testing for the consumer market. The digital platform is already in advanced development, and a Joint Ventu…
Genetic Analysis summarizes this year’s product development activities and looks ahead to 2024 (opens in a new tab)
The post Genetic Analysis summarizes this year’s product development activities and looks ahead to 2024 appeared first on Genetic Analysis.…
Genetic Analysis publishes information memorandum relating to the previously announced subsequent offering (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis announces final number of subscription rights received per existing share in the previously announced subsequent offering (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…